Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Vividion Therapeutics has raised $82 million in its second major round of financing, which included both new and old investors. Founded in 2014 based on technology from Scripps Research Institute professors Benjamin Cravatt, Phil Baran, and Jin-Quan Yu, Vividion uses chemical probes to map out the hidden pockets on difficult-to-drug proteins linked to cancer and inflammation. With this latest funding round, the company has more than $165 million in cash to pursue a pipeline of direct and allosteric inhibitors and targeted protein degraders.
This article has been sent to the following recipient: